Symbol="RGLS"
AssetType="Common Stock"
Name="Regulus Therapeutics Inc"
Description="Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of drugs that target microRNAs to treat a variety of diseases in the United States. The company is headquartered in San Diego, California."
CIK="1505512"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="25512600"
EBITDA="-29019000"
PERatio="None"
PEGRatio="-0.04"
BookValue="1.745"
DividendPerShare="0"
DividendYield="0"
EPS="-1.86"
RevenuePerShareTTM="0.071"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.372"
ReturnOnEquityTTM="-0.746"
RevenueTTM="5000000"
GrossProfitTTM="-18410000"
DilutedEPSTTM="-1.86"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="276.78"
AnalystTargetPrice="5.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="7.43"
PriceToBookRatio="0.586"
EVToRevenue="0.657"
EVToEBITDA="0.563"
Beta="1.647"
num_52WeekHigh="2.4"
num_52WeekLow="0.76"
num_50DayMovingAverage="1.394"
num_200DayMovingAverage="1.381"
SharesOutstanding="19475300"
DividendDate="2018-10-04"
ExDividendDate="None"
symbol="RGLS"
open="1.32"
high="1.36"
low="1.28"
price="1.31"
volume="5821.00"
latest_trading_day="2023-08-17"
previous_close="1.32"
change="-0.01"
change_percent="-1.1321%"
aroon_positive_momentum_days="58"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="58"
Volume_recent_avg="45537"
Change_recent_avg="0.01"
Delta_recent_avg="0.11"
Variance_recent_avg="0.06"
Change_ratio_recent_avg="0.3"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="58"
Aroon_momentum_negative="42"
image_negative_thumbnail_id_1="1130"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0163.jpeg"
image_negative_thumbnail_id_2="491"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0114.jpeg"
image_neutral_thumbnail_id_1="432"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_neutral_thumbnail_id_2="540"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_positive_thumbnail_id_1="609"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0099.jpeg"
image_positive_thumbnail_id_2="954"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0116.jpeg"
image_professor_thumbnail_id_1="1201"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
image_professor_thumbnail_id_2="1188"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
